能否靶向T细胞急性淋巴细胞白血病？
Can one target T-cell ALL?
作者信息
Ferrando Adolfo
机构信息
Institute for Cancer Genetics, Columbia University, 1130 St Nicholas Ave., ICRC 401B, New York, NY, 10032, USA.
出版信息
Best Pract Res Clin Haematol. 2018 Dec;31(4):361-366. doi: 10.1016/j.beha.2018.10.001. Epub 2018 Oct 17.
Abstract
Progress in our understanding of the central genes, pathways, and mechanisms in the pathobiology of T-cell acute lymphoblastic leukemia (T-ALL) has identified key drivers of the disease, opening new opportunities for therapy. Drugs targeting highly prevalent genetic alterations in NOTCH1 and CDKN2A are being explored, and multiple other targets with readily available therapeutic agents, and immunotherapies are being investigated. The molecular basis of T-ALL is reviewed here and potential targets and therapeutic targets discussed.
摘要
我们对T细胞急性淋巴细胞白血病（T-ALL）病理生物学中的核心基因、信号通路和机制的理解取得了进展，已确定了该疾病的关键驱动因素，为治疗带来了新机遇。针对NOTCH1和CDKN2A中高度普遍的基因改变的药物正在探索中，其他多种有现成治疗药物的靶点以及免疫疗法也在研究中。本文综述了T-ALL的分子基础，并讨论了潜在靶点和治疗靶点。
相似文献
1
Can one target T-cell ALL?能否靶向T细胞急性淋巴细胞白血病？
Best Pract Res Clin Haematol. 2018 Dec;31(4):361-366. doi: 10.1016/j.beha.2018.10.001. Epub 2018 Oct 17.
2
In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.γ-分泌酶抑制剂单独或与其他抗癌药物联合用于治疗T细胞急性淋巴细胞白血病的体外验证
Haematologica. 2008 Apr;93(4):533-42. doi: 10.3324/haematol.11894. Epub 2008 Mar 5.
3
New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.深入了解 Notch1 对 PI3K-AKT-mTOR1 信号轴的调控：γ-分泌酶抑制剂耐药 T 细胞急性淋巴细胞白血病的靶向治疗。
Cell Signal. 2014 Jan;26(1):149-61. doi: 10.1016/j.cellsig.2013.09.021. Epub 2013 Oct 16.
4
Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia.Notch1诱导的T细胞急性淋巴细胞白血病中Arf基因的阶段特异性肿瘤抑制作用
Blood. 2009 Nov 12;114(20):4451-9. doi: 10.1182/blood-2009-07-233346. Epub 2009 Sep 16.
5
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.PTEN-AKT与T细胞急性淋巴细胞白血病中NOTCH1导向治疗策略的相关性。
Haematologica. 2016 Sep;101(9):1010-7. doi: 10.3324/haematol.2016.146381.
6
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.γ-分泌酶抑制剂对NOTCH信号通路的抑制作用可激活RB通路，并促使T细胞急性淋巴细胞白血病细胞退出细胞周期。
Cancer Res. 2009 Apr 1;69(7):3060-8. doi: 10.1158/0008-5472.CAN-08-4295. Epub 2009 Mar 24.
7
More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.γ-分泌酶抑制剂在癌症治疗中的更多应用见解。
Oncologist. 2021 Feb;26(2):e298-e305. doi: 10.1002/onco.13595. Epub 2020 Nov 26.
8
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.PSEN1 选择性γ-分泌酶抑制剂联合激酶或 XPO-1 抑制剂可有效靶向 T 细胞急性淋巴细胞白血病。
J Hematol Oncol. 2021 Jun 24;14(1):97. doi: 10.1186/s13045-021-01114-1.
9
Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures.急性淋巴细胞白血病中对Notch1抑制的抗性蛋白质组学揭示了可靶向的激酶特征。
Nat Commun. 2021 May 4;12(1):2507. doi: 10.1038/s41467-021-22787-9.
10
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.在小鼠T细胞急性淋巴细胞白血病模型中靶向Notch1和mTOR信号通路。
Blood. 2009 Jun 11;113(24):6172-81. doi: 10.1182/blood-2008-02-136762. Epub 2009 Feb 26.
引用本文的文献
1
PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL.PIM1是T-ALL/LBL中JAK/STAT途径突变介导的致白血病作用的潜在治疗靶点。
NPJ Precis Oncol. 2024 Jul 20;8(1):152. doi: 10.1038/s41698-024-00638-2.
2
Identifying Candidate Gene Drivers Associated with Relapse in Pediatric T-Cell Acute Lymphoblastic Leukemia Using a Gene Co-Expression Network Approach.使用基因共表达网络方法鉴定与小儿T细胞急性淋巴细胞白血病复发相关的候选基因驱动因素。
Cancers (Basel). 2024 Apr 25;16(9):1667. doi: 10.3390/cancers16091667.
3
Targeted Treatment and Immunotherapy in High-risk and Relapsed/ Refractory Pediatric Acute Lymphoblastic Leukemia.高危和复发/难治性儿童急性淋巴细胞白血病的靶向治疗和免疫治疗。
Curr Pediatr Rev. 2023;19(2):150-156. doi: 10.2174/1573396318666220901165247.
4
NOTCH-ing up nucleotide metabolism in T-cell acute lymphoblastic leukemia.在 T 细胞急性淋巴细胞白血病中 Notch 调控核苷酸代谢。
Commun Biol. 2021 Jun 29;4(1):809. doi: 10.1038/s42003-021-02330-8.
5
The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.小儿 T 细胞急性淋巴细胞白血病的新治疗策略。
Int J Mol Sci. 2021 Apr 26;22(9):4502. doi: 10.3390/ijms22094502.
6
Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia.T细胞急性淋巴细胞白血病中NOTCH1信号通路靶向治疗的研究进展
Exp Hematol Oncol. 2020 Nov 13;9(1):31. doi: 10.1186/s40164-020-00187-x.
7
New Drug Repositioning Candidates for T-ALL Identified Human/Murine Gene Signature Comparison.确定的T-ALL新型药物重新定位候选物：人与小鼠基因特征比较
Front Oncol. 2020 Nov 9;10:557643. doi: 10.3389/fonc.2020.557643. eCollection 2020.
8
More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.γ-分泌酶抑制剂在癌症治疗中的更多应用见解。
Oncologist. 2021 Feb;26(2):e298-e305. doi: 10.1002/onco.13595. Epub 2020 Nov 26.
9
Genetic Heterogeneity of Esophageal Squamous Cell Carcinoma with Inherited Family History.具有遗传家族史的食管鳞状细胞癌的遗传异质性
Onco Targets Ther. 2020 Sep 3;13:8795-8802. doi: 10.2147/OTT.S262512. eCollection 2020.
10
Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia.单细胞DNA扩增子测序揭示了T细胞急性淋巴细胞白血病中的克隆异质性和进化。
Blood. 2021 Feb 11;137(6):801-811. doi: 10.1182/blood.2020006996.
本文引用的文献
1
Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.NT5C2 突变导致复发型淋巴细胞白血病硫嘌呤耐药的结构与机制。
Cancer Cell. 2018 Jul 9;34(1):136-147.e6. doi: 10.1016/j.ccell.2018.06.003.
2
The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols.存在突变和缺失的 PTEN 与接受 AIEOP-BFM ALL 方案治疗的儿童 T 细胞急性淋巴细胞白血病复发风险增加相关。
Br J Haematol. 2018 Sep;182(5):705-711. doi: 10.1111/bjh.15449. Epub 2018 Jun 25.
3
An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.一种用于治疗 T 细胞血液系统恶性肿瘤的现成型抗自杀 CAR-T。
Leukemia. 2018 Sep;32(9):1970-1983. doi: 10.1038/s41375-018-0065-5. Epub 2018 Feb 20.
4
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.NT5C2 突变体复发急性淋巴细胞白血病中的克隆进化机制。
Nature. 2018 Jan 25;553(7689):511-514. doi: 10.1038/nature25186. Epub 2018 Jan 17.
5
Targeted cellular immunotherapy for T cell malignancies.针对T细胞恶性肿瘤的靶向细胞免疫疗法。
Nat Med. 2017 Dec 7;23(12):1402-1403. doi: 10.1038/nm.4458.
6
Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.突变型 JAK3 信号会因野生型 JAK3 的缺失或 T-ALL 中继发性 JAK3 突变的获得而增强。
Blood. 2018 Jan 25;131(4):421-425. doi: 10.1182/blood-2017-07-797597. Epub 2017 Nov 29.
7
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.针对 T 细胞受体 β 链恒定区进行 T 细胞恶性肿瘤的免疫治疗。
Nat Med. 2017 Dec;23(12):1416-1423. doi: 10.1038/nm.4444. Epub 2017 Nov 13.
8
Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and fusion: A case report.达沙替尼与化疗用于一名伴有 融合的早期 T 细胞前体急性淋巴细胞白血病患者：病例报告
Exp Ther Med. 2017 Nov;14(5):3979-3984. doi: 10.3892/etm.2017.5046. Epub 2017 Aug 28.
9
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.突变 JAK3 磷酸化蛋白质组学分析预测 JAK3 抑制剂与 MEK/BCL2 抑制剂联合治疗 T 细胞急性淋巴细胞白血病的协同作用。
Leukemia. 2018 Mar;32(3):788-800. doi: 10.1038/leu.2017.276. Epub 2017 Aug 30.
10
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.儿童及青年T细胞系急性淋巴细胞白血病的基因组图谱
Nat Genet. 2017 Aug;49(8):1211-1218. doi: 10.1038/ng.3909. Epub 2017 Jul 3.
Zotero 插件